SRNE Sorrento Therapeutics Inc.

1.81
-0.06  -3%
Previous Close 1.87
Open 1.87
Price To Book 4.21
Market Cap 328,226,023
Shares 181,340,344
Volume 5,603,752
Short Ratio
Av. Daily Volume 5,898,762
Stock charts supplied by TradingView

NewsSee all news

  1. Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program

    STI-6991 is an I-CellTM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virusThe I-Cell vaccine is expected to elicit both T

  2. SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19

    ACE-MABTM is a proprietary bi-specific fusion protein that binds to the spike protein of coronaviruses, including SARS-CoV-2 and SARS-CoV, which is expected to block SARS-CoV-2 from binding and infecting respiratory

  3. SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19

    SAN DIEGO and BOSTON, March 23, 2020 (GLOBE NEWSWIRE) -- In response to the government call for rapidly deployable countermeasures, Sorrento Therapeutics, Inc. (NASDAQ:SRNE, Sorrento)) and SmartPharm Therapeutics Inc.

  4. SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)

    COVIDTRAPTM is a proprietary ACE2-Fc protein that binds to the S1 domain of the spike protein of the SARS-CoV-2 virus;COVIDTRAP is designed to block the SARS-CoV-2 virus from binding and infecting respiratory epithelial

  5. ServiceSource Announces Four New Appointments to Board of Directors

    Company appoints Andrew M. Baker, Jane Okun Bomba, John A. Meyer, and Robin L. Smith Additions expand ServiceSource's Board with respected world-class leaders Planned retirement of three directors at the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced February 28, 2018.
ZTlido (lidocaine patch 1.8%)
Pain associated with post-herpetic neuralgia (PHN)
Phase 1 data due 2020.
Anti-CD38 CAR-T
Multiple Myeloma
Phase 3 trial to commence 2Q 2020. Phase 1b final data due March 2020.
Resiniferatoxin
Osteoarthritis Knee
Phase 3 top-line data due 2H 2020.
SP-102
Lumbosacral radicular pain (sciatica)
BLA filing due 2020.
STI-002
Remicade (infliximab) biosimilar
Phase 1 data presented at American Academy of Pain Medicine - February 27, 2020.
Resiniferatoxin
Intractable Pain Associated with Cancer
Phase 1 IND filing due to be filed in the coming months - noted March 20, 2020.
STI-4398
Coronavirus COVID-19

Latest News

  1. Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program

    STI-6991 is an I-CellTM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virusThe I-Cell vaccine is expected to elicit both T

  2. SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19

    ACE-MABTM is a proprietary bi-specific fusion protein that binds to the spike protein of coronaviruses, including SARS-CoV-2 and SARS-CoV, which is expected to block SARS-CoV-2 from binding and infecting respiratory

  3. SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19

    SAN DIEGO and BOSTON, March 23, 2020 (GLOBE NEWSWIRE) -- In response to the government call for rapidly deployable countermeasures, Sorrento Therapeutics, Inc. (NASDAQ:SRNE, Sorrento)) and SmartPharm Therapeutics Inc.

  4. SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)

    COVIDTRAPTM is a proprietary ACE2-Fc protein that binds to the S1 domain of the spike protein of the SARS-CoV-2 virus;COVIDTRAP is designed to block the SARS-CoV-2 virus from binding and infecting respiratory epithelial

  5. ServiceSource Announces Four New Appointments to Board of Directors

    Company appoints Andrew M. Baker, Jane Okun Bomba, John A. Meyer, and Robin L. Smith Additions expand ServiceSource's Board with respected world-class leaders Planned retirement of three directors at the

  6. Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial

    Fourteen subjects with advanced cancer pain received epidural RTX (04 to 15 ug)Most common treatment-related adverse event was transient post-procedure related painThree subjects at the higher doses had rapid and marked

  7. Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference

    SAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )), announced today that Dr. Henry Ji, Chairman and CEO, will present at the 9th Annual LEERINK Partners Global

  8. Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global Healthcare Conference

    SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )), announced today that it will present at LEERINK Partners 9th Annual Global Healthcare Conference (Lotte New

  9. Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection

    SAN DIEGO and WARREN, N.J., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )) announced it has initated a clinical and manufacturing collaboration with Celularity, Inc.,

  10. Sorrento Board Rejects Latest Acquisition Proposal

    The latest non-binding proposal received on January 9, 2020 from a private equity fund to acquire a majority or all of the issued and outstanding shares of the company for "up to $7.00" per share significantly

  11. Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences

    Phase 1b/2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts. The program is expected to move to Phase III

  12. Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal

    SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento" or the "Company")), announced today that on January 9, 2020, it received a non-binding proposal from a private equity

  13. Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China

    SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (NASDAQ:SRNE) announced today that its partner Mabpharm (HK:2181) filed recently a New Drug Application for the Infliximab biosimilar antibody in

  14. Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors

    SAN DIEGO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )) announced today that Robin L. Smith, MD, MBA has been appointed to its Board of Directors. Dr. Smith is a

  15. Sorrento Announces New Board Member

    SAN DIEGO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )) announced today that Mr. Edgar Lee has been appointed to its Board of Directors. Mr. Lee is currently a

  16. Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal

    SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", or the "Company")), confirmed today that on November 23, 2019, it received an unsolicited, non-binding term

  17. Sorrento CEO to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )), announced today that Dr. Henry Ji, Chairman and CEO, will participate in upcoming investor conferences in

  18. Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences

    SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento's research team will

  19. Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering

    SAN DIEGO, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento")), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into

  20. Sorrento Therapeutics Announces $25 Million Registered Direct Offering

    SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento")), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into

  21. Scilex Announces New Medicaid Agreements with CA & FL

    PALO ALTO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE), is excited to announce that its subsidiary, Scilex

  22. Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak

    PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors in May of this year.

  23. Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

    SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE), announced that it has confidentially submitted a draft

  24. CBD Products Continue to Reap the Benefits of Legalization

    NEW YORK, Sept. 6, 2019 /PRNewswire/ -- The hemp industry has grown significantly over recent years as cannabis legalization has become more prominent. Notably, with the passage of the U.S. Farm Bill, the industry is

  25. Dr. Henry Ji to Participate in Multiple Investment Conferences in September 2019 to Provide Corporate Updates

    SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )), announced today that Dr. Henry Ji, Chairman and CEO, will participate in multiple investment conferences